Systematic Analysis of the Multiple Bioactivities of Green Tea through a Network Pharmacology Approach

Table 1

Enriched KEGG pathways.

Pathway ID	Term	Number of proteins	P value
hsa05214	Glioma	21	8.86E − 11
hsa05200	Pathways in cancer	39	2.41E − 09
hsa05215	Prostate cancer	22	8.26E − 09
hsa05223	Non-small-cell lung cancer	17	4.49E − 08
hsa05218	Melanoma	18	6.21E − 07
hsa04370	VEGF signaling pathway	15	9.00E − 06
hsa05212	Pancreatic cancer	13	5.89E − 05
hsa05213	Endometrial cancer	12	1.90E − 04
hsa04115	p53 signaling pathway	12	2.39E − 04
hsa05219	Bladder cancer	11	3.74E − 04
hsa04914	Progesterone-mediated oocyte maturation	13	8.84E − 04
hsa05222	Small cell lung cancer	14	8.84E − 04
hsa04664	Fc epsilon RI signaling pathway	14	8.84E − 04
hsa04510	Focal adhesion	20	1.16E − 03
hsa04722	Neurotrophin signaling pathway	18	1.68E − 03
hsa05220	Chronic myeloid leukemia	13	2.45E − 03
hsa04660	T cell receptor signaling pathway	15	3.03E − 03
hsa04012	ErbB signaling pathway	14	4.66E − 03
hsa04666	Fc gamma R-mediated phagocytosis	11	6.31E − 03
hsa04520	Adherens junction	9	7.74E − 03
hsa04662	B cell receptor signaling pathway	11	1.28E − 02
hsa05221	Acute myeloid leukemia	10	1.58E − 02
hsa00140	Steroid hormone biosynthesis	8	2.15E − 02
hsa04912	GnRH signaling pathway	15	2.43E − 02
hsa05210	Colorectal cancer	9	2.99E − 02
hsa05211	Renal cell carcinoma	11	3.47E − 02